Analysis of Adverse Drug Reactions Induced by SGLT-2 Inhibitors

doi:10.19803/j.1672-8629.2021.05.16

Abstract

Abstract: Objective To explore the characteristics and regularity of adverse drug reactions(ADR) induced by SGLT-2 inhibitors, so as to improve the safety of clinical medication. Methods CNKI, WanFang, VIP, PubMed, Embase and Medline database were retrieved from database building to November 28, 2019 and ADR induced by SGLT-2 inhibitors were analyzed retrospectively. Results A total of 40 cases of ADR induced by SGLT-2 inhibitors was enrolled in this study. Among them, 13 ADR were involved, and the top 3 types of ADR induced by SGLT-2 inhibitors were diabetic ketoacidosis (55.0%), acute pancreatitis (10.0%), fanconi syndrome (7.5%). Conclusion ADR induced by SGLT-2 inhibitors were varied, in which more attentions should be paid to new ADR such as fanconi syndrome, sweet syndrome and so on. During application of SGLT-2 inhibitors, the indications should be strict and close monitoring was necessary.

Key words: SGLT-2 inhibitors, adverse drug reactions, analysis

CLC Number:

R994.11

ZHANG Houjing, JI Liwei. Analysis of Adverse Drug Reactions Induced by SGLT-2 Inhibitors[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 478-482.

References

[1] Fioretto P,Zambon A,Rossato M,et al.SGLT2 inhibitors and the diabetic kidney[J].Diabetes Care,2016,39(suppl 2):S165-S171.
[2] Freitas HS,AnhêGF,Melo KF,et al.Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels:involvement of hepatocyte nuclear factor-1alpha expression and activity[J].Endocrinology,2008,149(2):717-724.
[3] Rahmoune H,Thompson PW,Ward JM,et al.Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulindependent diabetes[J].Diabetes,2005,54(12):3427-3434.
[4] Zelniker TA,Wiviott SD,Raz I,et al.SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes:a systematic review and meta-analysis of cardiovascular outcome trials[J].Lancet,2019,393(10166):31-39.
[5] Peters AL,Buschur EO,Buse JB,et al.Euglycemic diabetic ketoacidosis:a potential complication of treatment with sodium-glucose cotransporter 2 inhibition[J].Diabetes Care,2015,38(9):1687-1693.
[6] Linfoot P,Bergstrom C,Ipp E.Pathophysiology of ketoacidosis in Type 2 diabetes mellitus[J].Diabetic Med,2005,22(10):1414-1419.
[7] Daniele G,Xiong J,Solis-Herrera C,et al.Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes[J].Diabetes Care,2016,39(11):2036-2041.
[8] Burke KR,Schumacher CA,Harpe,SE.SGLT2 inhibitors:a systematic review of diabetic ketoacidosis and related risk factors in the primary literature[J].Pharmacotherapy,2017,37(2):187-194.
[9] Donnan JR,Grandy CA,Chibrikov E,et al.Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors:a systematic review and meta-analysis[J].BMJ Open,2019,9(1):e022577.
[10] Saad M,Mahmoud AN,Elgendy IY,et al.Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus:a meta-analysis of placebo-controlled randomized trials[J].Int J Cardiol,2017,228(2):352-358.
[11] FDA.Invokana-(canagliflozin)[prescribing information] Janssen pharmaceuticals,Inc[EB/OL].(2019-09-27)[2020-01-10].https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204042s032lbl.pdf.
[12] Balani AR,Grendell JH.Drug-induced pancreatitis:incidence,management and prevention[J].Drug Saf,2008,31(10):823-837.
[13] Badalov N,Baradarian R,Iswara K,et al.Drug-induced acute pancreatitis:an evidence-based review[J].Clin Gastroenterol Hepatol,2007,5(6):648-651.
[14] Chowdhary M,KabbaniA A,Chhabra A.Canagliflozin-induced pancreatitis:a rare side effect of a new drug[J].Ther Clin Risk Manag,2015,11(6):991-994.
[15] Fimognari FL,Corsonello A,Pastorell R,et al.Metformin-induced pancreatitis[J].Diabetes Care,2006,29(5):1183.
[16] Alsubaie S,Almalki MH.Metformin induced acute pancreatitis[J].Dermatoendocrinol,2013,5(2):317-318.
[17] Robert S.Merck manual of diagnosis and therapy[M].20th ed.New Jersey:Merck Research Laboratories,2018:1079.
[18] Esprit DH,Koratala A.Fanconi syndrome associated with SGLT2 inhibitor,canagliflozin[J].Nephrology,2018,23(5):493.
[19] Shawwa K,Samaha A.A case of fanconi syndrome in a patient taking canagliflozin for diabetes:a previously unreported catastrophic adverse effect[J].Am J Kidney Dis,2016,67(5):A99.
[20] Khan N,Tso K,Broussard J,et al.Canagliflozin-induced fanconi syndrome in a patient with previously unrecognized type 1 diabetes[J].Am J Health Syst Pharm,2019,76(23):1930-1933.
[21] FDA.Postmarket drug safety information for patients and providers:sodium-glucose cotransporter-2 (SGLT2) inhibitors.FDA[EB/OL].(2018-08-29)[2019-01-10].https://www.fda.gov/drugs/postmarket-drugsafety-information-patients-and-providers/sodiumglucose-cotransporter-2-sglt2-inhibitors (2019).
[22] Shen J,Yang J,Zhao B.A Survey of the FDA's adverse event reporting system database concerning urogenital tract infections and sodium glucose cotransporter-2 inhibitor use[J].Diabetes Ther,2019,10(3):1043-1050.
[23] Bersoff-Matcha SJ,Chamberlain C,Cao C,et al.Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors:a review of spontaneous postmarketing cases[J].Ann Intern Med,2019,170(11):764-769.
[24] Puckrin R,Saltiel MP,Reynier P,et al.SGLT-2 inhibitors and the risk of infections:a systematic review and meta-analysis of randomized controlled trials[J].Acta Diabetol,2018,55(5):503-514.
[25] Wilding J.SGLT2 inhibitors and urinary tract infections[J].Nat Rev Endocrinol,2019,15(12):687-688.
[26] Storgaard H,Gluud LL,Bennett C,et al.Benefits and harms of sodiumglucose co-transporter 2 inhibitors in patients with type 2 diabetes:a systematic review and meta-analysis[J].PLoS One,2016,11(11):e0166125.
[27] Zaccardi F,Webb DR,Htike ZZ,et al.Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus:systematic review and network meta-analysis[J].Diabetes obes metab,2016,18(8):783-794.
[28] Ra dholm K,Wu JH,Wong MG,et al.Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease,death and safety outcomes in type 2 diabetes-a systematic review[J].Diabetes Res Clin Pract,2018,140:118-128.
[29] Zhang L,Zhang M,Lyu Q,et al.Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and moderate renal function impairment:a systematic review and metaanalysis[J].Diabetes res clin pract,2018,140:295-303.
[30] Donnan JR,Grandy CA,Chibrikov E,et al.Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections:a systematic review and network meta-analysis of randomized controlled trials[J].CMAJ open,2018,6(4):E594-E602.
[31] Erythropoulou-Kaltsidou A,Polychronopoulos G,Tziomalos K.Sodium-glucose co-transporter 2 inhibitors and fracture risk[J].Diabetes Ther,2020,11(1):7-14.
[32] Azharuddin M,Adil M,Ghosh P,et al.Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus:A systematic literature review and bayesian network meta-analysis of randomized controlled trials[J].Diabetes Res Cclin Pract,2018,146:180-190.
[33] Neal B,Perkovic V,Mahaffey KW,et al.Canagliflozin and cardiovascular and renal events in type 2 diabetes[J].N Engl J Med,2017,377(21):644-657.
[34] Khouri C,Cracowski JL,Roustit M.SCLT-2 inhibitors and the risk of lower-limb amputation:is this a class effect?[J].Diabeles Obes Metab,2018,20(6):1531-1534.
[35] Fadini GP,Avogano A.SGLT2 inhibitors and amputations in the US FDA adverse event reporting system[J].Lancet Diabetes Eendocrinol,2017,5(9):680-681.
[36] Scheen AJ.Does lower limb amputation concern all SGLT2 inhibitors?[J].Nat Rev Endocrinol,2018,14(6):326-328.
[37] Ramachandra Pai RP,Kangath RV.Bilateral gangrene of fingers in a patient on empagliflozin:First case report[J].World J Diabetes,2019,10(2):133-136.
[38] Cai J,Ji LW.One case of palpitation induced by empagliflozin Tablets[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2019,16(8):506-507.